At Ventus, we are focused on discovering and developing novel therapeutics that target the innate immune system with the goal of addressing autoimmune diseases, inflammatory diseases, and cancer.

We are uniquely enabled by our field-leading structural immunology platform, a highly experienced management and drug discovery team that has delivered multiple marketed compounds, and leading academics spanning the fields of structural biology and immunology.

Guided by a patient-centric ethos, our aim is to rapidly advance multiple drug candidates. Our emerging pipeline focuses on the inflammasome and nucleic acid sensing pathways.